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to 40% of patients presenting with angina have no visual 
evidence of obstructive epicardial CAD on invasive coro-
nary angiography (ICA) [2]. The increasing use of inva-
sive diagnostic tests to assess key parameters of coronary 
physiology at the time of ICA, namely coronary pressure, 
flow and microvascular resistance assessment are providing 
new, clinically-relevant diagnostic information [3]. Addi-
tionally, coronary endothelial dysfunction may result in 
angina, and this may be assessed with vasoreactivity testing 
[4]. Grüntzig first recognised the importance of assessing 
the physiological significance of coronary lesions, measur-
ing the resting trans-lesional gradient pre- and post-balloon 
angioplasty [5]. However, the bulky balloon catheter lead 
to an overestimation of trans-lesional gradients, resting 
measurements were used due to no available hyperaemic 
agent, and the absolute trans-lesional gradient was meas-
ured rather than the relative reduction in perfusion pres-
sure. With technical advances, these barriers have almost 
completely been overcome [6–8].
The coronary vasculature may be artificially divided into 
three compartments [9]. The epicardial coronary arteries 
(diameter >500 µm) are predominantly capacitance vessels 
and in the healthy state offer little resistance to blood flow. 
The coronary microvasculature is the predominant site of 
auto-regulation of myocardial blood flow and resistance to 
coronary blood flow. Pre-arterioles (diameter 100–500 µm) 
are comprised of proximal and distal vessels, which are 
most responsive to changes in flow and pressure respec-
tively. Pre-arterioles regulate perfusion pressure into the 
subtended arteriolar compartment. Arterioles (diameter 
<100 µm) match myocardial blood supply and demand and 
are the predominant site of metabolic regulation of myo-
cardial blood flow [10, 11]. It is increasingly appreciated 
that structural abnormalities limiting myocardial blood 
flow may occur not just in the epicardial vessels but also 
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Introduction
Coronary artery disease (CAD) is a significant cause of 
morbidity and mortality worldwide [1]. Traditionally, 
angina pectoris is attributed to obstructive epicardial coro-
nary atherosclerotic plaque, which results in myocardial 
ischaemia due to supply-demand mismatch. However, up 
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in the microvasculature, and that functional abnormalities 
may also result in angina [12]. Comprehensive assessment 
of the structural and functional components of each coro-
nary compartment may be indicated, especially in the clini-
cal scenario of ‘angina with normal coronaries’. Fractional 
flow reserve (FFR) is the reference-standard method to 
define flow-limiting lesions in the epicardial coronary com-
partment. FFR use is increasing [13, 14], and the European 
Society of Cardiology gives FFR a class 1A indication for 
the assessment of intermediate severity stenosis (defined as 
50–90% diameter stenosis) [1, 15]. In the USA, the increas-
ing frequency of FFR guidance has also been stimulated by 
recent appropriate use criteria and some private insurance 
companies require evidence of ischaemia by FFR assess-
ment if percutaneous coronary intervention (PCI) is to be 
undertaken [16] (Fig. 1).
Assessment of epicardial coronary artery stenosis 
and angiographic‑physiological discordance
ICA is traditionally the standard reference test for the 
assessment of obstructive epicardial CAD. However, there 
is a poor correlation between visually-assessed anatomi-
cal stenosis severity on ICA and the physiological sig-
nificance of a stenosis in terms of reduction in myocardial 
blood flow [17]. In study of 1000 patients who underwent 
ICA, intra-vascular ultrasound (IVUS), and FFR, it was 
determined that quantitative coronary angiography (QCA) 
had a diagnostic accuracy of 66% compared with FFR. 
A significant QCA diameter stenosis (>50%) and a non-
significant FFR (>0.80) was predicted by older age, non-
left anterior descending artery lesions, absence of plaque 
rupture, shorter lesion length, larger minimum luminal 
cross-sectional area (MLA), less plaque burden, and worse 
angiographic minimal lumen diameter. The predictors for a 
non-significant QCA diameter stenosis (<50%) with a sig-
nificant FFR < 0.80 were younger age, LAD lesions, pres-
ence of plaque rupture, smaller MLA, and larger plaque 
burden [18].
Fractional flow reserve: theory, experimental 
validation and practical considerations
FFR is a pressure-derived index of the maximal blood flow 
in an epicardial coronary vessel in the presence of a ste-
nosis compared to the maximum flow in the hypothetical 
absence of a stenosis. At maximal hyperaemia during coro-
nary vasodilator administration, when coronary resistance 
is minimised, blood flow is approximately linearly related 
to coronary pressure within the physiological range of cor-
onary perfusion pressures [19].
In order to determine the physiological significance of a 
coronary lesion, a pressure-sensitive 0.014″ coronary wire 
is positioned distal to an epicardial coronary lesion. The 
pressure distal to the coronary stenosis is obtained from a 
pressure sensor 3 cm proximal to the tip of the wire. The 
pressure proximal to the stenosis is obtained from the coro-
nary guide catheter, which sits at the ostium of the coronary 
artery proximal to any obstruction. A bolus of 200–300 µg 
of intra-coronary glyceryl trinitrate is administered to pro-
voke epicardial vasodilation, and counteract any coronary 
wire-related spasm which may mimic a stenosis. Maximal 
hyperaemia of the microvasculature is most commonly 
induced with intravenous (140 µg/kg/min for at least 2 min) 
or intra-coronary (100–200 µg) adenosine. If there is a left-
dominant system or a right-dominant right coronary artery 
under study, then escalating doses may be used starting 
with 50 µg to avoid prolonged atrioventricular nodal block. 
FFR is calculated from the mean distal coronary pressure 
(Pd) indexed to the mean aortic pressure (Pa) obtained 
simultaneously at maximal hyperaemia: FFR = Pd/Pa [19]. 
The theoretical FFR value in a normal epicardial vessel 
without obstruction to blood flow is a ratio of 1.0. A clini-
cal threshold of ≤0.8 is used to define a significant coro-
nary stenosis [1] (Fig. 2).
In routine clinical practice, the myocardial FFR 
(FFRmyo) is measured, defined as the relative blood 
flow to the myocardium subtended by the coronary ves-
sel being interrogated. By measuring the coronary wedge 
pressure (Pw) during maximal hyperaemia, the influence 
on myocardial blood flow from sources other than the 
Fig. 1  Schematic representation of the comprehensive assessment 
of the structural and functional components of the epicardial and 
microvascular compartments of the coronary tree. CFR represents the 
vasodilatory capacity of the epicardial vessel being interrogated and 
the microvasculature that it subtends. FFR is the reference standard 
for the assessment of the functional significance and an epicardial 
coronary stenosis. The IMR is a specific measure or the microvas-
cular resistance being interrogated. Endothelial function, and epicar-
dial and microvascular spasm may be tested for with vasoreactivity 
testing. FFR fractional flow reserve, IMR index of microcirculatory 
resistance, CFR coronary flow reserve
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epicardial artery (such as collateral and venous flow) can 
theoretically be accounted for. This is impractical in most 
cases as it requires balloon inflation to interrupt antero-
grade flow and so Pw measurement is predominantly 
performed in vessels undergoing PCI or in a research set-
ting. The coronary FFR (or FFRcor) incorporates wedge 
pressure into its calculation, where FFRcor = [Pd − Pw]/
[Pa − Pw]. In clinical practice, the measurement of Pw 
does not significantly alter the measured FFR, and does 
not influence the decision for revascularisation [20]. In 
its original derivation, the calculation of FFR accounted 
for right atrial pressure (Pv) where, FFRmyo = [Pd − Pv]/
[Pa − Pv] [19]. Pragmatically, venous pressure is not usu-
ally measured in clinical practice to avoid central venous 
catheterisation, and Pv was not used for FFR calculation 
in the landmark clinical trials [21–23]. In usual practice, 
Pv has negligible influence on the measured FFR [24].
The experimental validity of determining rela-
tive blood flow (i.e. FFR) from pressure measurements 
obtained at hyperaemia was initially investigated in a 
canine model [25]. The first clinical validation in 45 
patients, compared FFR against a gold standard of three 
non-invasive ischaemia tests, interrogating different 
aspects of the ischaemic cascade: electrical (exercise 
electrocardiogram testing), perfusion (myocardial perfu-
sion thallium scintigraphy) and contractile (dobutamine 
stress echocardiography) [26]. In patients with a nega-
tive FFR (>0.75), 21 out of 24 patients had no evidence 
of inducible ischaemia on all three of the non-invasive 
modalities.
Practical considerations in the approach to FFR meas-
urement are always important. The operator should care-
fully ensure calibration steps with the console. The angio-
graphic catheter should be co-axial and not wedged. The 
FFR diagnostic wire should be positioned 6–9  cm from 
the guide catheter in the artery of interest (or in the distal 
half of the vessel). Resting pressure should be measured 
first before induction of hyperaemia, and if there are serial 
lesions, a pull-back recording should be made. Finally, the 
possibility of sensor-drift should be checked and if evident, 
calibration should be repeated (Fig. 3).
Induction of maximal hyperaemia
Only during hyperaemia when the microvascular resistance 
is minimised does the coronary pressure–flow relationship 
become linear within the physiological range of blood pres-
sure, which is a basic assumption for FFR. Hence, achiev-
ing maximal hyperaemia is key to avoiding false-negative 
FFR values. Adenosine is most commonly used in clinical 
Fig. 2  Schematic representation of fractional flow reserve measure-
ment. Pa proximal (aortic) pressure, Pd distal coronary pressure
Fig. 3  a FFR recording demonstrating the interrogation of a signifi-
cant coronary lesion with an FFR value below the clinical ischaemic 
threshold of 0.8. b Measurement of a coronary wedge pressure. c 
Pull-back assessment for pressure wire ‘drift’ following FFR meas-
urement
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practice, inducing vasodilation via agonism of the  A2A 
receptor, and thus minimising coronary resistance [27]. 
Intravenous infusion or intra-coronary bolus may be used 
[28]. A key advantage of intravenous infusion is that ‘pull-
back’ assessment may be performed to ascertain the ana-
tomical location of a ‘step-up’ in pressure gradient occurs 
(i.e. the location of a significant epicardial lesion) [29].
An appropriate response to adenosine should be con-
firmed at the time of administration (i.e. Increase in heart 
rate, reduction in systemic blood pressure and typical 
symptomatology), otherwise there is a risk of false-nega-
tive FFR values [30]. A common confounder is caffeine, a 
potent  A2A receptor antagonist [27], which reduces the vas-
odilatory response to adenosine and thus results in submax-
imal hyperaemia. Patients are routinely recommended to 
avoid caffeine consumption for >24 h prior to FFR assess-
ment [31]. If there is a lack of response to adenosine, it may 
be useful to increase the dosage (i.e. 140, 175, and 210 μg/
kg/min) to ensure maximal hyperaemia is achieved, and 
there is evidence that caffeine antagonism is overcome with 
high dose adenosine [32]. A number of vasodilator agents 
other than adenosine have been investigated, including 
intravenous regadenoson (a specific  A2A receptor agonist) 
[33], and intra-coronary sodium nitroprusside [34], nico-
randil [35], nitrate [36], and papaverine [31]. These agents 
produced approximately similar FFR values compared to 
adenosine [35]. Radiographic contrast medium injection 
can also induce hyperaemia, and has been proposed as an 
alternative to adenosine hyperaemic FFR. The Continuum 
of Vasodilator Stress From Rest to Contrast Medium to 
Adenosine Hyperemia for Fractional Flow Reserve Assess-
ment (CONTRAST) Study demonstrated an 85.8% diag-
nostic accuracy in reference to FFR at a cut-off of 0.83 
whereas alternative resting pressure indices, including rest-
ing Pd/Pa and the instantaneous wave free ratio  (iFR®), 
demonstrated a lower diagnostic accuracy of <80% in the 
763 lesions studied [30]. This result supports a conclusion 
that diagnostic accuracy increases with increasing magni-
tude of hyperaemia.
Resting pressure indices
The interest in resting physiology to estimate the functional 
significance of an epicardial stenosis was first explored by 
Grüntzig [5], and has recently been revisited. Compared 
to the FFR reference metric, alternative resting indices 
achieve a diagnostic accuracy of approximately 80% (80.4 
and 82.5% from the RESOLVE and ADVISE-II analyses 
respectively) when compared to FFR [37, 38]. This inter-
est has been prompted by the desire to avoid adenosine 
hyperaemia due to short-lived patient side-effects including 
flushing and dyspnoea, and the cost and limited availability 
of adenosine in some parts of the world. ‘Whole-cycle rest-
ing Pd/Pa′ is the distal coronary pressure indexed to aor-
tic pressure without the induction of hyperaemia, whereas 
 iFR® is defined as the pressure ratio at rest during a time 
interval starting 25% into diastole and ending 5 ms before 
onset of systole.  iFR® is calculated using proprietary soft-
ware, whereas resting Pd/Pa is available generically using 
any FFR system. For an FFR ischaemic threshold of ≤0.75, 
whole-cycle resting Pd/Pa cut-offs of ≤0.85 to ≥0.93 have 
been proposed (with a positive predictive value of 95% and 
negative predictive value of 95.7% respectively) [39].  iFR® 
was initially proposed by the ADVISE investigators as an 
adenosine-free test with a threshold of 0.83 being equiva-
lent to the clinical FFR threshold of 0.80 [37, 40], however, 
research by the VERIFY investigators confirmed that  iFR® 
is lowered significantly when measured during intravenous 
adenosine infusion [41]. This threshold has since been 
revised to 0.89 with a diagnostic accuracy of around 82.5% 
[38]. Using a hybrid algorithm which incorporates hyper-
aemic FFR measurements, patients whose  iFR® falls in the 
0.86–0.93 range receive adjunctive adenosine and undergo 
full FFR assessment due to diagnostic uncertainty in the so-
called ‘adenosine zone’. This accounts for up to 35–45% of 
cases undergoing assessment but results in greater diagnos-
tic accuracy versus FFR [42–44]. Clinical trials designed to 
assess health outcomes with iFR versus FFR-guided man-
agement are ongoing [45] (Fig. 4).
Morphological coronary stenosis and patient 
features influencing fractional flow reserve
Morphological characteristics of an epicardial coronary 
stenosis are relevant to the reduction in myocardial blood 
flow that a given lesion may cause. The pressure drop 
Fig. 4  Pyramid of diagnostic accuracy with invasive assessments of 
coronary physiology. Adapted from Johnson et al. [63]
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across a stenosis is defined by: ΔP = fQ + sQ2, where 
ΔP = change in pressure, f = the viscous frictional forces 
along a lesion [increasing linearly with blood flow (Q) 
as explained by Poiseuille’s Law], and s = the separation 
forces due to eddy formation at the exit from a stenosis 
(increasing with the square of blood flow, as explained 
by Bernoulli’s Law) [46, 47]. Accordingly, lesion-spe-
cific factors may impact on the measured FFR: (1) lesion 
length has a strong inverse correlation with FFR value, 
with a length of >20 mm suggested as the strongest mor-
phological determinant of functional significance [48, 
49]; (2) increasing lesion diameter stenosis (assessed by 
QCA) correlates with lower FFR values [48]; (3) increas-
ing lesion complexity (assessed by QCA) also predicts 
greater pressure losses due to flow separation and friction 
[50, 51]; (4) lipid-rich necrotic core coronary plaques 
have been associated with significant FFR values, inde-
pendent of diameter stenosis [52]. A potential explanation 
is that these vulnerable plaques have reduced vasodilator 
capacity and are therefore more likely to be ischaemia-
inducing (and therefore have significant FFR values). (5) 
Lesion location: as the volume of tissue that is subtended 
by a coronary stenosis increases so may the trans-lesional 
pressure gradient, and reduction in distal coronary pres-
sure [53].
Patient-related variables may affect the influence the 
FFR value: (1) for any given angiographic stenosis sever-
ity, the measured FFR values are higher with increasing age 
[54]. A putative explanation is age-related cardiac changes 
such as interstitial fibrosis may result in coronary microvas-
cular dysfunction; (2) for the same degree of angiographic 
stenosis severity, women are more likely to have higher 
FFR values [55, 56]. Potential explanations for this obser-
vation include an increased prevalence of microvascular 
dysfunction in females compared to males, and that females 
have a lower body surface area and lower myocardial mass 
subtended by each coronary artery compared to males; 
There is an inverse linear correlation between the measured 
FFR value and the mass of myocardium subtended by the 
vessel being interrogated [53].
Microvascular dysfunction is also relevant. If there is 
reversible microvascular dysfunction e.g. reflecting recov-
ery of microvascular function within a culprit artery post-
myocardial infarction, then Pd would expectedly reduce as 
reversible microvascular function improves. In other words, 
FFR may be inappropriately high. On the other hand, if 
microvascular dysfunction is fixed, then the FFR value 
would be expectedly stable. Therefore, the key question is 
whether or not the microcirculatory dysfunction is fixed 
or reversible. In this regard, measuring the index of micro-
circulatory resistance (IMR = mean  Pd × mean transit time, 
during hyperaemia), and whether or not there is reversibil-
ity, as reflected by the resistance reserve ratio [RRR = basal 
resistance index (mean Pd × mean transit time, at rest)/
IMR], may be helpful [57].
These lesion- and patient-specific variables are clinically 
relevant [58]: in a young patient, a proximal focal severe 
lesion in coronary vessel subtending a large myocardial 
mass, the losses due to separational forces will predomi-
nate. These lesions are more likely to have relatively pre-
served resting Pd/Pa values, with a significant increase in 
coronary flow across the lesion with hyperaemia resulting 
in a significant gradient and reduced FFR values. In con-
trast, in long moderate lesions, the frictional losses will 
predominate. There may be a relatively lower resting Pd/Pa 
and a more modest reduction in FFR with hyperaemia.
Rational for the ischaemic threshold based 
on the DEFER and FAME trials
In the original validation study [26], the FFR threshold for 
discriminating clinically significant lesion-level ischaemia 
was found to be 0.75. This threshold was confirmed in The 
Fractional Flow Reserve to Determine the Appropriateness 
of Angioplasty in Moderate Coronary Stenosis (DEFER) 
trial [21]. 325 patients who were planned to undergo PCI 
underwent FFR measurement. Patients with an FFR ≥ 0.75 
were randomised to deferral of PCI (defer group) or to 
undergo PCI (perform group), whereas those with an 
FFR < 0.75 underwent PCI as planned (reference group). 
There was no significant difference in the primary endpoint 
of absence of adverse cardiac events at 24 months follow-
up in the defer versus perform groups, demonstrating that 
patients with negative-FFR values (defined as >0.75) did 
not benefit from PCI when compared to medical therapy. 
At 15-years follow-up, there remained no significant dif-
ference in the rate of death in patients with functionally 
insignificant lesions (FFR > 0.75) that were managed with 
medical therapy, and there was a lower rate of myocardial 
infarction (MI) in the defer group compared to the perform 
group (2.2% vs. 10.0%, p = 0.03) [59].
A meta-analysis of study-level (n = 9173) and patient-
level (n = 6961) data similarly found the optimal FFR 
threshold for a composite endpoint of death, MI and 
revascularisation to be 0.75 [60]. As opposed to a binary 
cut-off, the measured FFR value has prognostic impor-
tance, with a spectrum of increasing clinical events with 
decreasing FFR value. This is one reason for why meas-
uring resting pressure indices alone, or adopting a hybrid 
strategy, may be less informative overall, since FFR is 
not routinely measured with these approaches. In clinical 
practice, patients with FFR values close to the treatment 
threshold i.e. 0.81–0.85 have a higher likelihood of future 
major adverse cardiac events compared to patients with a 
near normal FFR value i.e. 0.96–1.0 [60]. Patients with a 
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higher risk profile according to measured FFR may there-
fore warrant more aggressive secondary prevention strat-
egies compared to patients with near normal values.
To reliably exclude the presence of functionally sig-
nificant stenoses, a threshold of ≤0.80 is routinely used 
in clinical practice to increase measurement sensitivity. A 
threshold of ≤0.80 was used in the two FAME outcomes 
trials of FFR-guided PCI [22, 23]. This has produced 
diagnostic uncertainty for patients with FFR values of 
0.75–0.80 inclusive. For patients in this ‘grey zone’, phy-
sician decision-making informed by all clinical informa-
tion (e.g. anginal symptoms and non-invasive evidence 
of ischaemia) is especially important. A retrospective 
analysis included 1459 patients with proximal single-ves-
sel disease and FFR values in the grey zone (defined as 
0.76–0.80) and the neighbouring FFR strata (0.70–0.75, 
and 0.81–0.85) [61]. 449 (30%) patients underwent PCI, 
and 1010 (70%) were treated with medical therapy alone. 
In patients treated with medical therapy alone, there was 
a progressive decrease in MACE rates with increasing 
FFR value. In the grey zone, there was a trend towards 
an increased rate of death or MI in patients managed 
medically compared to PCI (25 vs. 9, p = 0.06). The 
Trial in Stable Intermediate Coronary Lesions and Grey-
zone FFR Values (gzFFR) (ClinicalTrials.gov Identifier: 
NCT02425969) will further inform this issue. In this 
trial, 110 patients with stable anginal symptoms who 
have undergone ICA and been found to have an epicar-
dial coronary stenosis with a ‘grey zone’ FFR (0.75–0.82 
inclusive) will be enrolled. Participants will be randomly 
assigned (1:1) to either optimal medical therapy (OMT) 
or PCI. Patients will undergo comprehensive physiologi-
cal assessment with acquisition of Doppler coronary 
flow and resistance data, as well as repeated FFR meas-
urements with incremental doses of adenosine. Stress 
perfusion cardiac magnetic resonance imaging at 3.0  T 
will be used to define the prevalence of inducible perfu-
sion abnormalities in the myocardium subtended by the 
study vessel. The primary outcome is angina severity at 
3 and 12 months with a key secondary endpoint of major 
adverse coronary events (MACE) at 3 and 12 months.
Another key consideration is which lesions should 
undergo FFR interrogation. The ESC guidelines define an 
intermediate stenosis as 50–90% [1]. In a diagnostic study 
of 200 patients [62], 47% of lesions defined as >70% diam-
eter stenosis were FFR-negative and 13% of lesions graded 
as <30% were FFR-positive. This suggests that rather than 
only using FFR for ‘intermediate’ stenoses, more discrete 
areas of coronary plaque should be interrogated, especially 
in younger patients, in epicardial vessels with proximal 
lesions subtending a large myocardial mass (namely left 
main stem and left anterior descending artery lesions), or 
lesions of long length.
Fractional flow reserve reproducibility
FFR measurement has been shown to be highly reproduc-
ible in clinical practice despite differences in the route of 
administration of hyperaemic agent, and variation in the 
hyperaemic agent used. The VERification of Instantaneous 
wave-Free ratio and FFR for the assessment of coronary 
artery stenosis severity in everydaY practice (VERIFY) 
[41] was a prospective study of 206 patients with an indica-
tion for FFR measurement. FFR was measured using intra-
venous adenosine (140 µg/kg/min administered for 2 min), 
with repeat measurements made after a 2-min rest period. 
FFR data were assessed by a central laboratory, with FFR 
reproducibility high  (r2 = 0.98) and narrow limits of agree-
ment (−0.04 to −0.04). Test–retest reliability for FFR 
in the CONTRAST Study was 0.019 indicative of a high 
reproducibility [63].
A key assumption of FFR measurement is that of maxi-
mal hyperaemia. Pd/Pa value may fluctuate during a hyper-
aemic recording and the minimum FFR may not be the 
same as the steady-state FFR. A reanalysis of the VERIFY 
dataset demonstrated that despite fluctuating haemodynam-
ics, the minimum measured FFR value is the most repro-
ducible. The authors have developed a novel ‘smart mini-
mum’ algorithm to select out the highest quality FFR data 
within a recording, which may help cardiologists identify 
the minimum FFR value for clinical decision-making [64].
Fractional flow reserve‑guided percutaneous 
coronary intervention in stable coronary artery 
disease: clinical outcomes studies
Following DEFER [21], the FFR versus Angiography for 
Guiding Percutaneous Coronary intervention (FAME) [22] 
and Fractional Flow Reserve-Guided PCI versus Medical 
Therapy in Stable Coronary Disease (FAME-2) [23] clini-
cal trials have established FFR-guided PCI as the standard 
of care in patients undergoing invasive management.
FAME tested the hypothesis that PCI guided by FFR 
measurement in patients with stable angina and multivessel 
CAD (defined as >50% stenosis in ≥2 main epicardial ves-
sels) would alter lesion classification and improve health 
and economic outcomes. After the decision to undertake 
PCI based on ICA, 1005 patients were randomised to 
FFR-guided PCI (PCI performed if FFR ≤ 0.8) or to con-
tinue with PCI guided by visual interpretation of the angio-
gram alone. The composite primary outcome of death, 
MI or repeat revascularisation at 1  year was lower in the 
FFR-guided group than in the angiography-guided group, 
[13.2% (67 patients) vs. 18.3% (91 patients), p = 0.02]. 
This difference was sustained at 2 years follow-up [65]. At 
5  years follow-up, there was no difference in the primary 
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endpoint between the FFR- and angiography-guided groups 
(28% vs. 31%, p = 0.3), but the absolute difference in events 
persisted, and this was driven by the difference in cardiac 
mortality [66].
FAME-2 enrolled 1220 patients with stable CAD who 
were undergoing invasive management and being con-
sidered for PCI of one or more angiographically severe 
stenosis. In the subset of patients with lesions with an 
FFR ≤ 0.80 that were amenable to PCI (n = 888), patients 
were randomised (1:1) to PCI of all lesions with OMT ver-
sus OMT alone without PCI. Patients with lesions with an 
FFR > 0.80 were not randomised but included in a follow-
up registry involving OMT alone. On the recommenda-
tion of the Data and Safety Monitoring Committee, the 
trial was stopped prematurely due to a statistically signifi-
cant reduction in hospital re-admission for urgent coronary 
revascularisation in the OMT group. It has been proposed 
that urgent revascularisation is a ‘soft’ endpoint, and as 
patients were aware they had a coronary lesion which had 
not undergone PCI, this may have influenced the likelihood 
of re-presentation to hospital [67]. Urgent coronary revas-
cularisation for the primary outcome was defined as urgent 
unplanned hospital admission with persistent or increas-
ing symptoms with or without ECG evidence of ischae-
mia (26.8%) or elevated cardiac biomarker levels (21.4%), 
and that the revascularisation be performed within 24 h of 
admission. Cardiologists blinded to the treatment group 
assignment adjudicated this outcome. After follow-up to 
2 years, the observed between-group difference in the pri-
mary outcome was maintained [68].
Fractional flow reserve in the diagnostic 
and treatment decision‑making pathway for stable 
coronary artery disease
FAME and FAME-2 provide a robust evidence base for 
the use of FFR-guided PCI in patients undergoing invasive 
management. FFR is also impactful earlier in the diagnos-
tic pathway. The diagnostic pathway for patients present-
ing with chest pain is complex, with variations in practice 
depending on the physician certainty of a clinical diagnosis 
of angina pectoris, and limitations of non-invasive ischae-
mia testing due to local availability and diagnostic accu-
racy. The Does Routine Pressure Wire Assessment Influ-
ence Management Strategy at Coronary Angiography for 
Diagnosis of Chest Pain (RIPCORD) study was designed 
to assess whether routine FFR measurement during diag-
nostic ICA would impact the management of patients 
when compared with visual assessment of the angiogram 
alone [62]. 200 patients with stable angina who had been 
referred for ICA were enrolled in 10 UK centres. The ICA 
was visually interpreted and a management plan formulated 
by the treating cardiologist. FFR was then measured in any 
epicardial vessel ≥2.25  mm with a ≥30% stenosis. The 
management plan (‘OMT alone’, ‘PCI’, ‘coronary artery 
bypass grafting (CABG)’, or ‘more information required’) 
changed in 26% and the number and localisation of func-
tionally significant stenoses was altered in 32%. Simi-
larly, The Registre Français de la FFR (R3F) [69] enrolled 
1075 consecutive patients from 20 centres who had sta-
ble angina who were undergoing ICA, and whom were 
found to have at least one intermediate coronary stenosis 
(defined as 30–65% stenosis). The results were consistent 
with those of RIPCORD, with the frequent reclassification 
of management with FFR-guided management compared 
to visual interpretation of the angiogram alone (47% of the 
cases). This evidence suggests that routine use of FFR at 
the diagnostic stage may improve the treatment decision-
making for patients by correctly identifying functionally 
significant coronary lesions facilitating lesion-level tai-
lored management. Whether this will result in improved 
clinical outcomes will be answered by a number of ongo-
ing studies: The proposed RIPCORD 2 study [70] will ran-
domise 1100 patients presenting with chest pain who are 
scheduled to undergo ICA to angiography-guided manage-
ment or FFR-guided management; The Functional Testing 
Underlying Coronary Revascularisation (FUTURE) trial 
(NCT01881555) will randomise 1728 patients chest pain 
with multi-vessel coronary artery disease diagnosed on 
ICA, to angiography alone versus angiography and FFR-
guided care, with a composite primary end point of death, 
MI, coronary revascularisation, and stroke at 1 year.
The RIPCORD study [62] confirmed that the manage-
ment of patients with stable angina with visual-interpreta-
tion of the ICA alone is flawed. Two seminal studies, The 
Optimal Medical Therapy with or without PCI for Stable 
Coronary Disease (COURAGE) trial [71] and The Syn-
ergy between PCI with Taxus and cardiac surgery (SYN-
TAX) study [72] trials, investigated revascularisation of 
patients with stable CAD. Both studies used visual-inter-
pretation of angiography alone to define significant epicar-
dial coronary stenosis. This will have almost certainly led 
to incorrect classification of functionally significant flow-
limiting lesions. The results of these studies may have pro-
duced different results had FFR-guided management been 
performed:
1. The COURAGE trial [71] randomised 2287 patients 
with stable angina and visually-assessed severe coro-
nary stenosis to PCI or no PCI. At a median follow-up 
of 4.6 years, there was no difference in the composite 
primary endpoint of death and MI. A key sub-study of 
COURAGE, demonstrated that patients with evidence 
of inducible ischaemia on SPECT imaging (≥10% 
ischaemic myocardium) (i.e. Those patients whom 
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FFR-guided assessment would classify) who were ran-
domised to PCI, had significant reductions in induc-
ible ischaemia and in the annual rate of death and MI 
[73]. This forms the basis for the ‘ischaemia hypoth-
esis’ and that PCI may improve outcomes in patients 
with stable CAD and a moderate to large ischaemic 
burden. This question will be investigated by The Inter-
national Study of Comparative Health Effectiveness 
with Medical and Invasive Approaches (ISCHEMIA) 
trial (NCT01471522). ISCHEMIA (n = 8000) tests the 
hypothesis that an initial invasive strategy of coronary 
angiography followed by PCI if feasible, in addition to 
OMT, will reduce the primary composite endpoint of 
cardiovascular death or non-fatal MI in patients with 
at least moderate ischaemia on stress imaging, com-
pared with an initial conservative strategy of OMT 
alone with coronary angiography reserved for failure 
of OMT. The invasive strategy involves FFR-guided 
revascularisation of ‘intermediate’ coronary stenoses 
(50–80% diameter stenosis), routine revascularisation 
for lesions >80% severity and no revascularisation for 
lesions <50% severity. The trial is currently enrolling 
patients worldwide.
2. The SYNTAX study, randomised 1800 patients with 
left main stem and multivessel CAD to PCI or CABG 
[72]. SYNTAX demonstrated significantly increased 
rates of major adverse cardiac or cerebrovascular 
events (MACCE) at 12 months in those who underwent 
angiography-guided PCI compared to CABG (17.8% 
vs. 12.4%), failing to meet the criterion of non-inferior-
ity for PCI. At 5-year follow-up in patients with a low 
SYNTAX score (an angiographically-defined anatomi-
cal scoring tool used to describe the complexity of epi-
cardial atherosclerotic CAD) there was no difference 
in MACCE in the PCI and CABG groups (32·1% vs. 
28·6%, p = 0·43). However, in patients with interme-
diate or high SYNTAX scores, there was significantly 
increased MACCE with PCI compared to CABG 
(intermediate score, 36·0% vs. 25·8%, p = 0·008; high 
score, 44·0% vs. 26·8%, p < 0·0001) [74]. Would the 
results of SYNTAX have been different had patients 
undergone FFR-guided PCI? The functional SYNTAX 
score only includes and scores lesions which are flow-
limiting (FFR ≤ 0.80). Using this score, in 497 patients 
from the FAME cohort, 32% of patients were reclassi-
fied and moved to lower risk SYNTAX score tertiles 
[75]. A retrospective analysis of 627 patients undergo-
ing FFR-guided CABG found FFR-guided CABG to be 
associated with fewer graft anastomoses, and did not 
result in a higher event rate (median 33.1 months fol-
low-up). Further data will be provided by The Compar-
ison of Fractional Flow Reserve-Guided Percutaneous 
Coronary Intervention and Coronary Artery Bypass 
Graft Surgery in Patients With Multivessel Coronary 
Artery Disease (FAME 3) study (NCT02100722) [76] 
which will randomise 1500 patients with multivessel 
CAD to FFR-guided PCI or CABG in patients with 
the primary endpoint of MACCE at 1-year follow-up 
(Fig. 5).
Fractional flow reserve measurement in specific 
situations
The evidence for FFR-guided PCI in patients with stable 
CAD is supported by landmark clinical trials. In compar-
ison, there is a smaller but growing literature on the role 
Fig. 5  Indications for the use 
on FFR-guided care in the diag-
nostic and invasive management 
of patients with stable CAD, 
and the relevant completed and 
ongoing FFR-guided clinical tri-
als (black boxes), MR-INFORM 
[102], CE-MARC2 [103], RIP-
CORD [62], RIPCORD-2 [70], 
COURAGE [71], ISCHEMIA, 
DEFER [21], FAME [22], 
FAME-2 [23], FAME-3
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of FFR in specific situations encountered in daily clinical 
practice.
1. Left main stem stenosis FFR measurement of inter-
mediate left main stem stenosis is associated with 
favourable outcomes. In 213 patients with angiographi-
cally equivalent left main stem stenosis, the prog-
nosis of patients who were medically managed if the 
FFR > 0.80 was similar to those with FFR ≤ 0.80 who 
underwent CABG (5-year event-free survival 74.2% 
vs. 82.8% respectively, p = 0.50) [77]. A pooled meta-
analysis of 6 studies (n = 525) investigating FFR-
guided revascularisation of left main stem stenosis 
found no statistically significant difference between 
patients undergoing revascularisation if the FFR was 
significant, compared to patients being deferred inter-
vention if the FFR was negative [78].
2. Bifurcation lesions With provisional stenting strategies, 
FFR assessment of the jailed side branch is feasible 
and safe: 110 patients undergoing PCI to bifurcation 
lesions had FFR measured in the jailed side branch. 
PCI to the side branch was performed if FFR < 0.75 
[79]. FFR measurement was then repeated post-PCI 
and at 6 months follow-up, with post-PCI FFR ≥ 0.75 
achieved in 92%. There was no significant change in 
the FFR values in the side branch lesions that under-
went PCI compared to those that did not, and there was 
no difference in 9-month cardiac event rate (4.6 vs. 
3.7% respectively, p = 0.7) when clinical outcomes of 
the study cohort were compared with 110 patients with 
similar bifurcation lesions undergoing angiographic-
guided PCI.
3. Surgical bypass grafts FFR-guided PCI of intermediate 
stenosis in arterial and venous surgical bypass grafts 
is valid: a retrospective analysis included 223 patients 
with a history of previous CABG who presented with 
stable or unstable anginal symptoms, and who had evi-
dence of an intermediate lesion in either an arterial or 
venous graft [80]. 65 patients underwent FFR assess-
ment with PCI performed if the FFR ≤ 0.80, whereas 
158 patients underwent angiography-guided PCI. At a 
median follow-up of 3.8  years, the primary outcome 
of MACCE was significantly lower in the FFR-guided 
compared angiography-guided group (18 vs. 77, 
p = 0.043).
Fractional flow reserve measurement 
post‑percutaneous coronary intervention
Rather than using visual interpretation of the angiogram 
alone to determine successful PCI, FFR may be measured 
post-PCI to inform this decision. A registry of 750 patients 
found a post-PCI value of <0.90 to predict worse outcomes 
[81]. As well as relating to the target lesion and inadequate 
stent deployment, a persistent gradient post-PCI may relate 
to diffuse atherosclerotic disease. This may be elicited by 
an FFR pullback recording along the length of the epicar-
dial artery. Importantly, FFR pull-back recordings were not 
performed in this registry.
Following post-dilation, if there is a persistent gradi-
ent at the site of the target lesion, intra-coronary imaging 
with IVUS or optical coherence tomography (OCT) may 
be indicated [15]. Knowledge of the mechanism underly-
ing a persistent gradient post-PCI is important to ascer-
tain, and may inform further therapeutic decisions, as these 
patients may represent with ongoing angina symptoms. A 
multicentre study of 240 patients presenting with NSTEMI, 
randomised patients (1:1) to either angiographic- or OCT-
guided PCI [82]. There was a statistically significant 
increase in the primary endpoint of the post-PCI FFR value 
in the OCT-guided compared to the angiographic-guided 
group (0.94 vs. 0.92, p = 0.005), with OCT revealing the 
persistent gradients to be related to stent under-expansion 
(42%), stent malapposition (32%), and incomplete lesion 
coverage (20%).
Fractional flow reserve measurement in acute 
coronary syndromes
The diagnostic validity of FFR has been questioned in 
acute coronary syndrome (ACS) patients and guidelines 
state that FFR may be measured in intermediate coronary 
lesions >5 days after the index event [83]. This is due to 
the potential for athero-thrombotic milieu to result in cul-
prit artery microvascular obstruction, and a reduced phar-
macological vasodilator response (resulting in inadequate 
hyperaemia and thus a key assumption of FFR is invalid), 
and therefore ‘false negative’ FFR values.
The FAMOUS-NSTEMI trial [84] randomised 350 
medically stabilised non-ST-elevation MI patients to either 
routine FFR-guided management versus standard invasive 
management. An initial treatment decision was made fol-
lowing ICA and before FFR measurement. Where feasible, 
FFR was then measured in all vessels with >30% diameter 
stenosis, but in patients randomised to angiographic guid-
ance alone, the FFR results remained blinded. The primary 
outcome was the between-group difference in the propor-
tion of patients allocated to optimal medical therapy alone, 
and this occurred more frequently in the FFR-guided group 
compared to the angiography-guided group (22.7% vs. 
13.2%; p = 0.022). In other words, the use of FFR reduced 
revascularisation. There was no difference in MACE 
between the groups. As in the stable CAD population, a 
marked discordance was seen between the angiographic 
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visual stenosis severity and functional significance defined 
by FFR. An FFR result was obtained in all participants with 
only two coronary dissections occurring due to the pressure 
wire, indicating routine FFR measurement was feasible and 
safe. There were no adverse events relating to intravenous 
adenosine.
FFR is not diagnostically valid when measured in the 
culprit artery of patients with an acute ST-elevation MI 
(STEMI). On the other hand, it may be diagnostically use-
ful for the assessment of coronary disease in non-culprit 
arteries. Non-culprit FFR measurement (performed follow-
ing treatment of the culprit lesion) in STEMI is reproduci-
ble when repeated at an interval of 35 ± 4 days [85]. Recent 
data on complete revascularisation of non-culprit vessels in 
the setting of STEMI has led to renewed interest in non-
culprit FFR measurement in acute STEMI. The DANAMI-
3-PRIMULTI trial [86] enrolled 627 patients presenting 
with STEMI and >1 angiographically significant stenosis 
in addition to the infarct-related artery. Patients were ran-
domised 1:1 to infarct-related artery only PCI or to com-
plete FFR-guided revascularisation prior to discharge. At a 
median follow-up of 27  months, there was a significantly 
increased primary endpoint (all-cause mortality, non-fatal 
re-infarction, and ischaemia-driven revascularisation of 
lesions in non-infarct-related arteries) in the infarct-related 
artery only PCI group compared to the complete FFR-
guided revascularisation group (22% vs. 13%, p = 0.004). 
This functional assessment strategy is in contrast to the pre-
ventive PCI strategy of all non-culprit vessel lesions >50% 
visual diameter stenosis in the PRAMI trial [87]. The ongo-
ing COMPARE-ACUTE (NCT01399736), COMPLETE 
(NCT01740479), FRAME-STEMI (NCT02715518), FULL 
REVASC (NCT02862119) and FAIO (NCT02637440) tri-
als will provide further evidence on FFR-guided care in 
STEMI patients.
Comprehensive invasive assessment of coronary 
physiology
FFR assesses the functional significance of an epicardial 
stenosis. Angina may result from abnormalities in other 
compartments, and the same coronary wire used to meas-
ure FFR, may be simultaneously used to interrogate the 
microvasculature (by indicator-thermodilution) allowing a 
more complete assessment of a patient’s coronary physiol-
ogy at the time of ICA, while providing prognostic data to 
guide management [88]. In addition to IMR and RRR, the 
assessment of coronary flow reserve (CFR) provide com-
plementary information and can aid in the differentiation 
of a patient’s symptoms due to focal or diffuse epicardial 
disease, microvascular disease, or both [89]. Although the 
importance of reduced CFR (secondary to epicardial or 
microvascular disease) in defining adverse prognosis has 
been clearly demonstrated [90], the role and prognostic 
importance of the interrogation of the microvascular com-
partment alongside the epicardial vessel with FFR meas-
urement is yet to be defined.
Non‑invasive estimates of fractional flow reserve: 
what’s coming next?
Quantitative flow ratio (QFR) is a novel method for assess-
ing the functional significance of intermediate coronary 
stenosis without the use of a coronary guidewire [91]. Fol-
lowing demarcation of vascular contours on orthogonal 
hyperaemic angiographic cine video-fluoroscopy acquisi-
tions, a 3-dimensional QCA coronary reconstruction is 
formed using QFR software. A QFR value is then produced 
using computational fluid dynamics, corrected for the 
(user-defined) TIMI (Thrombolysis in Myocardial Infarc-
tion) frame count. In a validation cohort of 84 vessels from 
73 patients with intermediate coronary lesions, QFR had 
a diagnostic accuracy for identifying lesions with an inva-
sive FFR ≤ 0.8 of 87% [92]. The Wire-free Invasive Func-
tional Imaging (WIFI) (NCT02795585) and the FAVOR II 
Europe (Holm NR, personal communication) studies will 
evaluate the feasibility and diagnostic accuracy of QFR 
measured using QCA during coronary angiography using 
virtual on-line reconstruction compared with invasively 
measured FFR as the reference.
Virtual FFR (vFFR) provides an estimated FFR value 
from rotational angiographic video-fluoroscopy. Hyperae-
mic acquisitions are not required. In a validation cohort of 
19 patients vFFR and invasive FFR were measured. There 
was a good agreement between vFFR and the invasively 
measured FFR, with a deviation from the measured values 
of ±0.06 [93].
FFR may be estimated non-invasively from computed 
tomography coronary angiography (FFR-CT) using pro-
prietary software which applies 3-dimensional blood flow 
simulations using the principles of computational fluid 
dynamics. The DISCOVER-FLOW study [94] estimated 
FFR-CT from 159 arteries in 103 patients who also under-
went ICA and FFR measurement, and reported a diagnostic 
accuracy of 84.3%. The HEARTFLOW-NXT study [95] of 
251 patients and 484 vessels similarly compared FFR-CT 
with invasively measured FFR and found a diagnostic accu-
racy of 86% on a per-vessel analysis. FFR-CT estimation 
may be limited by significantly calcific CAD, and technical 
factors which may reduce image quality (motion artifact, 
tachycardia, arrhythmia). The PLATFORM trial suggested 
that use of FFR-CT could lead to substantial reductions 
in unnecessary ICA and related health economic benefits 
[96, 97]. Exciting new studies, including ADVANCE and 
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SYNTAX III, will probe the expanding clinical potential 
and utility of this technology [98, 99].
Conclusion
For the functional assessment of an epicardial stenosis, a 
continuum exists from coronary angiography alone, to rest-
ing indices, to contrast-induced hyperaemia, to adenosine 
hyperaemic FFR. FFR-guided PCI in patients with stable 
CAD is well established with a robust evidence-base while 
the prognostic evidence for alternate indices is less well-
established. FFR-guided PCI improves health outcomes 
and does so with improved cost-effectiveness compared to 
optimal medical therapy alone [100, 101]. Ongoing clinical 
trials will help to define the role of FFR assessment along-
side non-invasive ischaemia testing in the diagnostic path-
way of patients presenting with chest pain.
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